ACM
BDTX icon

Atika Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Atika Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-69,874
Closed -$2.95M – 109
2020
Q2 		$2.95M Sell
69,874
-25,126
-26% -$925K 0.38% 80
2020
Q1 		$2.37M Buy
+95,000
New +$2.89M 0.45% 62

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Atika Capital Management's BDTX Position: Q3 2020 in Review

Atika Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q3 2020, closing a stake of 69,874 shares — an estimated $2.95M sold.

Atika Capital Management first reported a position in BDTX in Q1 2020 and held it in 2 quarters. The position peaked at $2.95M in Q2 2020. 88 funds tracked by Wall St. Rank hold BDTX as of Q3 2020.

  • Atika Capital Management reported no remaining Black Diamond Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Atika Capital Management sold 69,874 Black Diamond Therapeutics shares in Q3 2020, an estimated $2.95M.
  • Atika Capital Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 2 quarters.
  • Atika Capital Management's Black Diamond Therapeutics position peaked at $2.95M in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2020.

Based on Atika Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.